Skip to main content
Erschienen in: Cardiovascular Intervention and Therapeutics 1/2024

Open Access 10.11.2023 | Original Article

Halftime rotational atherectomy: a unique concept for diffuse long severely calcified lesions

verfasst von: Kenichi Sakakura, Hiroyuki Jinnouchi, Yousuke Taniguchi, Takunori Tsukui, Yusuke Watanabe, Kei Yamamoto, Masaru Seguchi, Hideo Fujita

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 1/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Rotational atherectomy (RA) is technically more difficult in a diffuse calcified lesion than in a focal calcified lesion. We hypothesized that taking a halftime can be another option for RA to the diffuse calcified lesions. Halftime was defined as at least one long break during RA, in which an operator pulled out the Rotablator system from the guide catheter before crossing the lesion. This study aimed to compare the complications between RA with and without halftime. We included 177 diffuse long severely calcified lesions (lesion lengths ≥ 30 mm) that required RA, and divided those lesions into a halftime group (n = 29) and a no-halftime group (n = 148). The primary outcome was periprocedural myocardial infarction (MI). The reference diameter was smaller in the halftime group than in the no-halftime group [1.82 (1.70–2.06) mm versus 2.17 (1.89–2.59) mm, p = 0.002]. The total run time was longer in the halftime group than in the non-halftime group [133.0 (102.0–223.0) seconds versus 71.5 (42.0–108.0) seconds, p < 0.001]. Although creatinine kinase (CK) and CK–myocardial band (MB) was significantly higher in the halftime group than in the no-halftime group [CK: 156 (97–308) U/L versus 99 (59–216) U/L, p = 0.021; CK–MB: 15 (8–24) U/L versus 5 (3–15) U/L, p < 0.001], periprocedural MI was not observed in the halftime group. In conclusion, periprocedural MI was not observed in RA with halftime. This preliminary study suggests that halftime RA may be a safe option for diffuse severely calcified lesions.

Graphical abstract

Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1007/​s12928-023-00968-1.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Rotational atherectomy (RA) has been the cornerstone for the percutaneous coronary intervention (PCI) to severely calcified lesions [15]. Among severely calcified lesions, RA is technically more difficult in a diffuse long calcified lesion than in a focal short calcified lesion, because the lesion length is closely associated with the occurrence of complications during RA [6, 7]. The clinical expert consensus document on RA from the Japanese association of cardiovascular interventions and therapeutics (CVIT) proposes an algorithm for the diffuse long calcified lesions [8, 9]. In the algorithm, halfway RA is suggested if there is a steep angle within the lesion [10, 11]. However, when halfway RA is not applicable for the lesion, the options to ablate the whole diffuse long lesion are limited. The burr-size down or the exchange of RotaWire (Marlborough, MA, USA) is described in the algorithm [8, 9]. Moreover, the combination of the burr-size down and the exchange of RotaWire may be useful [12].
ST-segment elevation is common in RA to a diffuse long calcified lesion, and such ST-segment elevation reflects coronary slow flow, which varies from mild slow flow [thrombolysis in myocardial infarction (TIMI) flow grade 2] to severe slow flow (TIMI flow grade ≤ 1) [13, 14]. It may be important to take a sufficient break than to keep ablating the lesions without a break, when sustained ST-segment elevation is observed. Because the diameter of the drive shaft sheath of Rotablator (Boston Scientific, Marlborough, MA, USA) is 4.3 Fr (1.43 mm) [8, 9], it may be necessary to pull out the Rotablator system from the guide catheter to restore the sufficient coronary flow, which requires a long break like halftime rather than a short break between each session. We hypothesized that taking a long break (halftime) irrespective of changes of burr-size or RotaWire can be another option for RA to the diffuse long calcified lesions. The purpose of this study was to compare the clinical outcomes in RA to the diffuse severely calcified lesions between RA with and without halftime.

Methods

This was a retrospective, single-center study. We reviewed 673 consecutive coronary lesions that were treated with RA in our institution during the period from November 2014 to March 2022. Indications for RA in our institution are the following: 1) angiographically moderately or severely calcified lesions, 2) diffuse lesions expected to be difficult to stent, and 3) ostial lesions [7, 15]. The primary outcome was periprocedural myocardial infarction (MI), which was defined as either an increase in creatine kinase–myocardial band (CK–MB) above 10 × upper limit normal (ULN) or CK–MB above 5 × ULN with development of new pathological Q waves according to the SCAI definition [16]. The secondary outcomes were other complications, such as slow flow just after RA, final TIMI flow grade ≤ 2, vessel perforation (type III) due to burr, and in-hospital death (irrespective of procedural complications).
The study was approved by the institutional review board of the Saitama Medical Center, Jichi Medical University (S22-125), and written informed consent was waved by the institutional review board of the Saitama Medical Center, Jichi Medical University, because of the retrospective study design. All procedures were in accordance with the Declaration of Helsinki. All methods were performed in accordance with relevant guidelines and regulations.
In most cases, RA was selected as the primary RA strategy, defined as RA before any attempt of balloon dilatation, whereas in some cases, RA was selected as the secondary RA strategy, defined as RA after unsuccessful balloon dilatation or unsuccessful balloon delivery. In the primary RA strategy, RA was performed using standard techniques. The lesion was crossed with a 0.014-inch conventional guidewire. Of 177 lesions, intravascular imaging including intravascular ultrasound (IVUS) or optical coherent tomography (OCT) before RA was tried in 129 lesions (72.9%). However, intravascular imaging devices could not cross the lesion in 65 lesions (36.7% of all lesions, 50.4% of tried lesions). Thus, intravascular imaging before RA was not available in 113 lesions (63.8% of all lesions). After intravascular imaging, a 0.014-inch conventional guidewire was exchanged for a 0.009-inch RotaWire floppy or RotaWire extra-support guidewire using a microcatheter. The RA burr was subsequently advanced over the wire to a position proximal to the lesion. Blood pressure (BP) and heart rate were recorded immediately before RA. The initial rotational speed was set within the conventional range (140,000–190,000 rpm) with the burr proximal to the lesion, and several lesions were randomly allocated to 140,000 rpm or 190,000 rpm [15]. The burr was activated and moved forward with a slow pecking motion. Each run time was < 30 s, and care was taken to avoid a decrease in rotational speed > 5000 rpm. Total run time was defined as the sum of each run time (high-speed mode). Total run time does not include either the interval time between the sessions or halftime. Furthermore, total run time does not include the time when the dynaglide mode is activated. The initial burr-size was either 1.25 mm, 1.5 mm, or 1.75 mm. After the burr passed the lesion, the burr was removed using the dynaglide mode or trapping balloon technique [17]. The presence of coronary flow was confirmed by injecting sufficient contrast medium immediately after the burr had been removed. An intra-aortic balloon pump (IABP) was inserted via a femoral artery before RA in high-risk cases such as those with severe left-ventricular dysfunction, unprotected left main stenosis, or severe 3-vessel disease.
Halftime was defined as at least one long break during RA, in which an operator pulled out the Rotablator system from the guide catheter before crossing the lesion. An operator needs to pull out the Rotablator system from the guide catheter when the burr-size down or the exchange of RotaWire is performed. Therefore, the lesions which required the burr-size down or the exchange of RotaWire before crossing the lesion were included in the halftime group. Furthermore, the lesions which required a long break (pull out the Rotablator system from the guide catheters) without burr-size down or exchange of RotaWire were also included in the halftime group. The definitions of hypertension, diabetes mellitus, and dyslipidemia are described elsewhere [7]. Estimate glomerular filtration rate (eGFR) was calculated using the MDRD formula (18). ACS was defined as ST-segment elevation MI, non-ST-segment elevation MI, or unstable angina [15]. The reference diameter and lesion length were calculated by quantitative coronary angiography. Offline, computer-based software QAngio XA 7.3 (MEDIS Imaging Systems, Leiden, The Netherlands) was used for quantitative coronary angiography. Calcification was identified as readily apparent radiopacities within the vascular wall at the site of the stenosis, and was classified as severe (radiopacities noted without cardiac motion before contrast injection generally compromising both sides of the arterial lumen) [19]. The burr-to-artery ratio was defined as the burr size divided by the reference diameter.

Statistical analysis

Data are presented as a percentage for categorical variables, a mean ± standard deviation (SD) for normally distributed continuous variables, or a median (Q2) and inter-quartile range (Q1 -Q3) for non-normally distributed continuous variables. The Wilk–Shapiro test was performed to determine if the continuous variables were normally distributed. Normally distributed continuous variables were compared between the 2 groups using Student’s t test. Otherwise, continuous variables were compared using a Mann–Whitney U test. Categorical data were compared using a Fisher’s exact test. One-to-one propensity-score matching was performed as supplemental analysis. Halftime RA was set as a dependent variable, whereas parameters that were clinically relevant for complications in RA, such as age, male sex, estimated GFR, culprit lesion in acute coronary syndrome, reference diameter, and lesion length, were set as independent variables [7, 20, 21]. Because the number of the halftime RA group was 29, we limited independent variables as above 6 variables. For matching, the match tolerance was set as a width of 0.25 multiplied by the SD of the propensity score distribution [10, 22]. Case–control matching found 27 matches with maximizing matching performance. All reported P values were determined by two-sided analysis, and P-values < 0.05 were considered significant. All analyses were performed with IBM SPSS statistics version 25 (Chicago, IL, USA).

Results

Of 673 lesions, we excluded 441 lesions, in which the lesion length was less than 30 mm. Then, we excluded 55 lesions, in which halfway RA was performed. The final study consisted of 177 lesions. The lesions were classified into a halftime group (n = 29) and a no-halftime group (n = 148) according to the presence or absence of halftime. The study flowchart is shown in Fig. 1, and the concept of halftime RA is illustrated in Fig. 2.
Four different approaches were performed in the halftime group. The breakdown of the halftime group was as follows: [1] the burr-size down (n = 10), [2] the exchange of RotaWire (n = 6), [3] the combination of burr-size down and exchange of RotaWire (n = 2), and [4] the restarting RA with same burr-size and same RotaWire (n = 11). The comparison of patient and lesion characteristics between the no-halftime group and the halftime group is shown in Table 1. The patient characteristics except angiotensin-converting enzyme inhibitors/angiotensin receptor blockers treatment were similar between the 2 groups. The reference diameter was significantly smaller in the halftime group than in the no-halftime group, whereas the lesion length was similar between the 2 groups.
Table 1
Comparison of patients and lesions characteristics between the no-halftime group and the halftime group
 
All
(n = 177)
No-halftime group
(n = 148)
Halftime group
(n = 29)
p value
Patient characteristics
 Age (years)
75.0 (68.0–79.5)
75.0 (68.3–79.0)
74 (67.5–80.5)
0.596
 Men—n, (%)
128 (72.3)
105 (70.9)
23 (79.3)
0.496
 Overweight (BMI ≥ 25 kg/m2)—n, (%)
56 (31.6)
44 (29.7)
12 (41.4)
0.275
 Hypertension—n, (%)
172 (97.2)
143 (96.6)
29 (100)
0.593
 Diabetes mellitus—n, (%)
99 (55.9)
80 (54.1)
19 (65.5)
0.309
 Hyperlipidemia—n, (%)
161 (91.0)
135 (91.2)
26 (89.7)
0.729
 Current smoker—n, (%)
28 (15.9) (n = 176)
23 (15.5)
5 (17.9) (n = 28)
0.779
 Chronic renal failure (creatinine > 2 mg/dl)—n, (%)
52 (29.4)
46 (31.1)
6 (20.7)
0.373
 Estimated GFR (mL/min/1.73m2)
66.5 (16.5–94.0)
65.2 (13.1–92.8)
76.6 (41.8–102.3)
0.091
 Left-ventricular ejection fraction (%)
58.0 (44.2–66.0) (n = 138)
58.5 (47.1–66.9) (n = 112)
57.9 (37.6–63.8) (n = 26)
0.238
 Chronic renal failure on hemodialysis—n, (%)
45 (25.4)
40 (27.0)
5 (17.2)
0.353
 History of hospitalization caused by heart failure – n, (%)
39 (22.0)
30 (20.3)
9 (31.0)
0.223
 Statin treatment—n, (%)
158 (89.3)
132 (89.2)
26 (89.7)
1.000
 ACE inhibitors/ARBs treatment—n, (%)*
125 (70.6)
100 (67.6)
25 (86.2)
0.047
 Beta blockers treatment—n, (%)
139 (78.5)
115 (77.7)
24 (82.8)
0.629
Lesion characteristics
 Culprit lesion in acute coronary syndrome—n, (%)
34 (19.2)
27 (18.2)
7 (24.1)
0.448
 Culprit lesion in acute coronary syndrome with visible thrombus- n, (%)
0
0
0
-
 Chronic total occlusion – n, (%)
10 (5.6)
9 (6.1)
1 (3.4)
1.000
 In-stent lesion – n, (%)
8 (4.5)
8 (5.4)
0
0.356
Target coronary artery
0.240
 Left main- left anterior descending artery—n, (%)
135 (76.3)
116 (78.4)
19 (65.5)
 
 Left circumflex artery—n, (%)
6 (3.4)
5 (3.4)
1 (3.4)
 
 Right coronary artery—n, (%)
36 (20.3)
27 (18.2)
9 (31.0)
 
Specific target coronary artery
 Ostial left main – n, (%)
0
0
0
^
 Ostial left anterior descending artery – n, (%)
27 (15.3)
22 (14.9)
5 (17.2)
0.778
 Ostial left circumflex artery – n, (%)
1 (0.6)
1 (0.7)
0
1.000
 Ostial right coronary artery—n, (%)
8 (4.5)
5 (3.4)
3 (10.3)
0.125
 Any ostial lesion – n, (%)
36 (20.3)
28 (18.9)
8 (27.6)
0.315
 Reference diameter (mm)
2.09 (1.83–2.51)
2.17 (1.89–2.59)
1.82 (1.70–2.06)
0.002
 Lesion length (mm)
40.67 (34.72–50.04)
40.96 (34.99–49.76)
40.22 (34.12–52.71)
1.000
Lesion angle
0.903
 Mild angulation (< 30º)
93 (52.5)
79 (53.4)
14 (48.3)
 
 Moderate angulation (30-60º)
70 (39.5)
57 (38.5)
13 (44.8)
 
 Severe angulation (≥ 60º)
14 (7.9)
12 (8.1)
2 (6.9)
 
 Angiographically severe calcification
177 (100)
148 (100)
29 (100)
-
 Pre-procedural TIMI-flow grade ≤ 2
30 (16.9)
23 (15.5)
7 (24.1)
0.281
Data are expressed as median and inter-quartile range or number (percentage). A Mann–Whitney U test was used for continuous variables, and a Fisher exact test was used for categorical variables, GFR glomerular filtration rate, TIMI Thrombolysis in myocardial infarction, ACE inhibitors  angiotensin-converting enzyme inhibitors, ARBs  angiotensin II receptor blockers, *One patient received angiotensin receptor neprilysin inhibito,
The comparison of procedural characteristics between the 2 groups is shown in Table 2. The number of used burrs was significantly higher in the halftime group than in the no-halftime group. The initial and final burr-to-artery ratio was significantly higher in the halftime group than in the no-halftime group. The total run time was significantly longer in the halftime group than in the non-halftime group. Final procedures were similar between the 2 groups.
Table 2
Comparison of procedural characteristics between the no-halftime group and the halftime group
 
All
(n = 177)
No-halftime group
(n = 148)
Halftime group
(n = 29)
p value
Primary RA strategy – n, (%)
149 (84.2)
124 (83.8)
25 (86.2)
1.000
Guiding catheter size and system
0.576
 6Fr—n, (%)
7 (4.0)
5 (3.4)
2 (6.9)
 
 7Fr—n, (%)
160 (90.4)
134 (90.5)
26 (89.7)
 
 8Fr—n, (%)
10 (5.6)
9 (6.1)
1 (3.4)
 
Intra-aortic balloon pump support—n, (%)
17 (9.6)
16 (10.8)
1 (3.4)
 
RotaWire floppy as initial RA guidewire
139 (78.5)
120 (81.1)
19 (65.5)
0.082
Number of used burrs
0.001
 1
136 (76.8)
122 (82.4)
14 (48.3)
 
 2
40 (22.6)
26 (17.6)
14 (48.3)
 
 3
1 (0.6)
0
1 (3.4)
 
Initial burr size
 < 0.001
 1.25-mm
70 (39.5)
67 (45.3)
3 (10.3)
 
 1.5-mm
104 (58.8)
78 (52.7)
26 (89.7)
 
 1.75-mm
3 (1.7)
3 (2.0)
0
 
Final burr size
0.721
 1.25-mm
69 (39.0)
59 (39.9)
10 (34.5)
 
 1.5-mm
78 (44.1)
63 (42.6)
15 (51.7)
 
 1.75-mm
14 (7.9)
13 (8.8)
1 (3.4)
 
 2.0-mm
16 (9.0)
13 (8.8)
3 (10.3)
 
Initial burr-to-artery ratio
0.66 ± 0.16
0.64 ± 0.15
0.78 ± 0.17
 < 0.001
Final burr-to-artery ratio
0.67 (0.57–0.82)
0.66 (0.56–0.78)
0.74 (0.64–0.89)
0.011
Total run time (seconds)
78.0 (45.0–126.5)
71.5 (42.0–108.0)
133.0 (102.0–223.0)
 < 0.001
Mean single run time (seconds)
12.0 (9.7–16.0)
12.0 (9.7–15.9)
11.6 (9.5–16.0)
0.784
Mean rotational speed (× 1000 rpm)
176.8 (171.4–180.4)
176.8 (168.5–180.3)
179.1 (174.5–182.9)
0.068
Maximum speed reduction during RA (rpm)
6000 (5000–10000) (n = 172)
6000 (4000–8750) (n = 144)
8000 (6000–11000) (n = 28)
0.003
Systolic blood pressure just before RA (mm Hg)
147 (134–168)
147 (133–166)
153 (132–173)
0.623
Diastolic blood pressure just before RA (mm Hg)
75 (68–84)
75 (69–84)
74 (62–85)
0.382
Heart rate just before RA (per minute)
69 (62–78)
70 (61–79)
67 (62–73)
0.286
Final procedure
1.000
 RA + balloon including drug-coating balloon—n, (%)
9 (5.1)
8 (5.4)
1 (3.4)
 
 RA + drug-eluting stent—n, (%)
162 (91.5)
134 (90.5)
28 (96.6)
 
 RA + drug-eluting stent + drug-coating balloon – n, (%)
3 (1.7)
3 (2.0)
0
 
RA + covered stent for perforation—n, (%)¶
3 (1.7)
3 (2.0)
0
 
Data are expressed as median and inter-quartile range or number (percentage). A Mann–Whitney U test was used for continuous variables, and a Fisher exact test was used for categorical variables. A case did not have perforation after RA, but required covered stent after stent implantation
The comparison of complications and outcomes between the 2 groups is shown in Table 3. The incidence of slow flow just after RA was higher in the halftime group than in the no-halftime group without reaching statistical significance. Although CK and CK–MB at the next day of RA was significantly higher in the halftime group than in the no-halftime group, neither periprocedural MI nor in-hospital death was observed in the halftime group.
Table 3
Comparison of complications and outcomes between the no-halftime group and the halftime group
 
All
(n = 177)
No-halftime group
(n = 148)
Halftime group
(n = 29)
p value
Complications and outcomes
 Slow flow just after RA – n, (%)
42 (23.7)
31 (20.9)
11 (37.9)
0.058
 Final TIMI flow grade ≤ 2 – n, (%)
1 (0.6)
1 (0.7)
0
1.000
 Vessel perforation (Type III) due to burr – n, (%)
2 (1.1)
2 (1.4)
0
1.000
 Periprocedural myocardial infarction – n, (%)
1 (0.6)
1 (0.7)
0
1.000
 Creatinine kinase at the next day of RA (U/L)
106 (66–229)
99 (59 – 216)
156 (97 – 308)
0.021
 Creatinine kinase-myocardial band at the next day of RA (U/L)
6 (3 – 18)
5 (3 – 15)
15 (8 – 24)
 < 0.001
 In-hospital death (irrespective of procedural complications)
1 (0.6)
1 (0.7)
0
1.000
Data are expressed as median and inter-quartile range or number (percentage). A Mann–Whitney U test was used for continuous variables, and a Fisher exact test was used for categorical variables
The comparison of patient and lesion characteristics between the matched no-halftime group and the matched halftime group is shown in Supplemental Table 1. The reference diameter as well as the lesion length were similar between the matched 2 groups. The comparison of procedural characteristics between the matched 2 groups is shown in Supplemental Table 2. The number of used burrs was significantly higher in the matched halftime group than in the matched no-halftime group. The comparison of complications and outcomes between the matched 2 groups is shown in Supplemental Table 3. The incidence of slow flow just after RA was similar between the matched 2 groups.

Discussion

We included 177 diffuse severely calcified lesions that underwent RA, and divided them into the no-halftime group (n = 148) and the halftime group (n = 29). The breakdown of the halftime group was as follows: [1] the burr-size down (n = 10), [2] the exchange of RotaWire (n = 6), [3] the combination of burr-size down and exchange of RotaWire (n = 2), and [4] the restarting RA with same burr-size and same RotaWire (n = 11). The reference diameter was significantly smaller in the halftime group than in the no-halftime group, whereas the lesion length was similar between the 2 groups. Total run time was significantly longer in the halftime group than in the no-halftime group. Although CK and CK–MB at the next day of RA was significantly higher in the halftime group than in the no-halftime group, neither periprocedural MI nor in-hospital death was observed in the halftime group. Our results suggest the possibility of halftime RA as an alternative option for diffuse severely calcified lesions.
Among halftime RA approaches, the burr-size down is a standard approach when an operator feels difficulty to cross the diffuse long lesions [8, 9]. Although this approach is well established among RA experts, there are no clinical studies that investigate the safety and efficacy of the burr-size down approach. In our cohort, approximately one-third of the halftime group used this approach, which suggests that the burr-size down may be useful to ablate the whole lesion without increasing complications. The exchange of RotaWire is also a well-established approach when an operator feels difficulty to cross the diffuse long lesions. There are 2 ways in the exchange of RotaWire. One is from RotaWire floppy to RotaWire extra-support, and the other is from RotaWire extra-support to RotaWire floppy. The former way is more commonly used than the latter way among RA experts. In our results, all cases with exchange of RotaWire adopted the former way. The exchange of RotaWire would modify the guidewire bias, which may facilitate the advancement of the burr. The combination of the burr-size down and the exchange of RotaWire can be the last resort for an uncrossable diffuse long lesion. It is natural for RA experts to select this approach, if the second burr or the second RotaWire does not work. The fourth approach is to restart RA with same burr and same RotaWire. This approach has not been recognized as an option for the diffuse long lesions. The concept of this approach is to take a halftime to stabilize the situation, and then restart RA with the same system if coronary flow is fully recovered. In our cohort, more than one-third of the halftime group used this approach. This approach does not require additional cost. If this approach does not work, operators can consider other approaches such as burr-size down. As compared to the former 3 halftime approaches, this approach (restart RA with the same burr and same RotaWire) is a novel halftime RA. The details of each halftime approach are summarized in Table 4.
Table 4
The details of each halftime approach
 
Burr-size down (n = 10)
Exchange of RotaWire (n = 6)
Combination of the burr-size down and the exchange of RotaWire (n = 2)
Restarting RA with same burr size and same RotaWire (n = 11)
Notes
Standard approach when an operator feels difficulty to cross the diffuse long lesions
All 6 cases used a RotaWire floppy as initial RotaWire. Then, exchanged to Extra-Support Wire
The combination of the burr-size down and the exchange of RotaWire would be the last resort for an uncrossable diffuse long lesion
This approach has not been recognized for the diffuse long lesions. Just take a halftime to stabilize the situation, and then restart RA with the same system
Strength
This approach is well-established among RA experts
This approach is also established among RA experts
It is natural to select this approach, if the second burr or the second RotaWire does not work
This approach does not require additional cost. If this approach does not work, an operator can consider other approaches such as burr-size down
Weakness
The second burr requires additional cost
The second RotaWire requires additional cost
The second burr and RotaWire require additional cost
The same system (burr and RotaWire) may not work after halftime
Rationale
The second (small) burr would require less energy than the first burr to cross the lesion
Different guidewire bias by the second RotaWire would work for crossing
Combination of burr-size down and exchange of RotaWire
If taking halftime was decided by ST-segment elevation or transient slow flow rather than the lesion’s hardness, we could restart RA without changing the burr size or RotaWire after ST-segment resolution or recovery of slow flow
The most important step in halftime RA is to stop RA when a marked ST-segment elevation is observed during RA. Unlike slow flow in the treatment of acute coronary syndrome, slow flow during RA progress gradually. If mild slow flow (TIMI flow grade 2) is properly addressed, the progression to severe slow flow (TIMI flow grade ≤ 1) is uncommon. However, if an operator ignores the signs of mild slow flow such as chest pain or ST-segment elevation, the progression to severe slow flow can occur, which results in periprocedural MI or subsequent procedure-related death. Since ST-segment elevation precedes slow flow in most cases, the decision-making to take a halftime highly depends on the appearance of marked or sustained ST-segment elevation during RA. The second important step in halftime RA is to pull out the RA system from the guide catheter. Because the diameter (1.43 mm) of the drive shaft sheath of Rotablator is larger than that of the small burr, the presence of the RA system within coronary artery would impede the recovery from slow flow. Since the drive shaft sheath of Rotablator is radiolucent, it is difficult for operators to recognize the position of the derive shaft sheath during RA. Furthermore, when intracoronary vasodilators such as nitroprusside are injected, the presence of the RA system would prevent those vasodilators from reaching to the distal coronary vascular bed. The third step in halftime RA is to wait for the recovery of coronary flow. Although the complete ST resolution may be difficult to achieve, a TIMI-grade 3 coronary flow is necessary to restart RA. Operators can spend the waiting time by performing intravascular imaging such as intravascular ultrasound. Finally, operators can select an appropriate approach among 4 different approaches (the burr-size down, the exchange of RotaWire, the combination of the burr-size down and the exchange of RotaWire, and restarting RA with same burr and same RotaWire).
Clinical implications of the present study should be noted. Because the coronary calcification represents the advancement of atherosclerosis, patients who undergo RA often have other comorbidities. RA to the diffuse severely calcified lesion may be performed in the context of complex and high-risk intervention in indicated patients (CHIP) [23]. Since severe slow flow can be fatal in CHIP, the option to prevent severe slow flow is of utmost importance. Our group previously proposed halfway RA especially for severely angulated lesions [10, 11]. Halfway RA, which is a combination of RA and balloon dilatation, is an option to prevent severe complications, such as vessel perforation or burr entrapment [10, 11]. However, since halfway RA mostly ablates the proximal half of the lesion, halfway RA may not work for some diffuse long lesions, especially severe calcification at the distal half of the lesions. Halftime RA, which is intended for ablating the whole lesion, may be an alternative option to prevent severe slow flow for any types of severely calcified lesions.
Since this study is a single-center, retrospective, observational study, there is a risk of patient selection bias and group selection bias. Because we experienced typical cases of halftime RA (restarting RA with same burr and same RotaWire) in the middle of the study period, we selected halftime RA more frequently after those cases, which can be a selection bias. Although care was taken to avoid a decrease in rotational speed > 5000 rpm, a decrease of > 5000 rpm was frequently observed in this study lesions. This means that our care might not be enough to prevent a decrease of > 5000 rpm or a decrease of > 5000 rpm might be unavoidable for diffuse long severely calcified lesions. Furthermore, although total run time did not include either the interval time between the sessions or halftime, total run time was significantly longer in the halftime than in the no-halftime group. It is unclear whether halftime RA strategy increases the ablation time itself or lesions in the halftime group were more severely calcified lesions. We did not define long break or halftime by the actual length of a break. However, it takes at least several minutes to pull out the Rotablator system from the guide catheter and reinsert the Rotablator system into the guide catheter. Although we conducted a propensity-score matching to adjust clinical background between the no-halftime group and the halftime group, the number of generated pairs was small. This preliminary study was conducted to generate a hypothesis that halftime RA can be a safe option for diffuse severely calcified lesions. Future studies are warranted to assess the safety and efficacy of halftime RA using a large sample size.

Conclusions

Although CK and CK–MB at the next day of RA was significantly higher in RA with halftime than in RA without halftime, neither periprocedural MI nor in-hospital death was observed in RA with halftime. Halftime RA may be an alternative option for diffuse severely calcified lesions.

Acknowledgements

The authors acknowledge Ryo Kokubo, M.E.; Kohei Matsuda, M.E.; and all staff in the catheter laboratory in Jichi Medical University, Saitama Medical Center for their technical support in this study.

Declarations

Conflict of interest

Dr. Sakakura has received speaking honoraria from Abbott Vascular, Boston Scientific, Medtronic Cardiovascular, Terumo, OrbusNeich, Japan Lifeline, Kaneka, and NIPRO; he has served as a proctor for Rotablator for Boston Scientific, and he has served as a consultant for Abbott Vascular and Boston Scientific. Prof. Fujita has served as a consultant for Mehergen Group Holdings, Inc. Other authors have no conflicts of interest to declare.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Anhänge

Supplementary Information

Below is the link to the electronic supplementary material.
Literatur
1.
Zurück zum Zitat Kini A, Marmur JD, Duvvuri S, Dangas G, Choudhary S, Sharma SK. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1000 patients. Catheter Cardiovasc Interv. 1999;46(3):305–11.CrossRefPubMed Kini A, Marmur JD, Duvvuri S, Dangas G, Choudhary S, Sharma SK. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1000 patients. Catheter Cardiovasc Interv. 1999;46(3):305–11.CrossRefPubMed
2.
Zurück zum Zitat Barbato E, Carrié D, Dardas P, Fajadet J, Gaul G, Haude M, et al. European expert consensus on rotational atherectomy. EuroIntervention. 2015;11(1):30–6.CrossRefPubMed Barbato E, Carrié D, Dardas P, Fajadet J, Gaul G, Haude M, et al. European expert consensus on rotational atherectomy. EuroIntervention. 2015;11(1):30–6.CrossRefPubMed
3.
Zurück zum Zitat Sharma SK, Tomey MI, Teirstein PS, Kini AS, Reitman AB, Lee AC, et al. North American expert review of rotational Atherectomy. Circ Cardiovasc Interv. 2019;12(5): e007448.CrossRefPubMed Sharma SK, Tomey MI, Teirstein PS, Kini AS, Reitman AB, Lee AC, et al. North American expert review of rotational Atherectomy. Circ Cardiovasc Interv. 2019;12(5): e007448.CrossRefPubMed
4.
Zurück zum Zitat Hamana T, Kawamori H, Toba T, Nishimori M, Tanimura K, Kakizaki S, et al. Prediction of the debulking effect of rotational atherectomy using optical frequency domain imaging: a prospective study. Cardiovasc Interv Ther. 2023;38(3):316–26.CrossRefPubMedPubMedCentral Hamana T, Kawamori H, Toba T, Nishimori M, Tanimura K, Kakizaki S, et al. Prediction of the debulking effect of rotational atherectomy using optical frequency domain imaging: a prospective study. Cardiovasc Interv Ther. 2023;38(3):316–26.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Sharma SK, Dangas G, Mehran R, Duvvuri S, Kini A, Cocke TP, et al. Risk factors for the development of slow flow during rotational coronary atherectomy. Am J Cardiol. 1997;80(2):219–22.CrossRefPubMed Sharma SK, Dangas G, Mehran R, Duvvuri S, Kini A, Cocke TP, et al. Risk factors for the development of slow flow during rotational coronary atherectomy. Am J Cardiol. 1997;80(2):219–22.CrossRefPubMed
7.
Zurück zum Zitat Sakakura K, Taniguchi Y, Yamamoto K, Tsukui T, Jinnouchi H, Seguchi M, et al. Modifiable and unmodifiable factors associated with slow flow following rotational atherectomy. PLoS ONE. 2021;16(4): e0250757.CrossRefPubMedPubMedCentral Sakakura K, Taniguchi Y, Yamamoto K, Tsukui T, Jinnouchi H, Seguchi M, et al. Modifiable and unmodifiable factors associated with slow flow following rotational atherectomy. PLoS ONE. 2021;16(4): e0250757.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Sakakura K, Ito Y, Shibata Y, Okamura A, Kashima Y, Nakamura S, et al. Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics. Cardiovasc Interv Ther. 2021;36(1):1–18.CrossRefPubMed Sakakura K, Ito Y, Shibata Y, Okamura A, Kashima Y, Nakamura S, et al. Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics. Cardiovasc Interv Ther. 2021;36(1):1–18.CrossRefPubMed
9.
Zurück zum Zitat Sakakura K, Ito Y, Shibata Y, Okamura A, Kashima Y, Nakamura S, et al. Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics: update 2023. Cardiovasc Interv Ther. 2023;38:141–62.CrossRefPubMedPubMedCentral Sakakura K, Ito Y, Shibata Y, Okamura A, Kashima Y, Nakamura S, et al. Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics: update 2023. Cardiovasc Interv Ther. 2023;38:141–62.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sakakura K, Taniguchi Y, Yamamoto K, Wada H, Momomura SI, Fujita H. Halfway rotational atherectomy for calcified lesions: Comparison with conventional rotational atherectomy in a propensity-score matched analysis. PLoS ONE. 2019;14(7): e0219289.CrossRefPubMedPubMedCentral Sakakura K, Taniguchi Y, Yamamoto K, Wada H, Momomura SI, Fujita H. Halfway rotational atherectomy for calcified lesions: Comparison with conventional rotational atherectomy in a propensity-score matched analysis. PLoS ONE. 2019;14(7): e0219289.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Sakakura K, Taniguchi Y, Matsumoto M, Wada H, Momomura S, Fujita H. How should we perform rotational atherectomy to an angulated calcified lesion? Int Heart J. 2016;57(3):376–9.CrossRefPubMed Sakakura K, Taniguchi Y, Matsumoto M, Wada H, Momomura S, Fujita H. How should we perform rotational atherectomy to an angulated calcified lesion? Int Heart J. 2016;57(3):376–9.CrossRefPubMed
12.
Zurück zum Zitat Taniguchi Y, Sakakura K, Mukai Y, Yamamoto K, Momomura SI, Fujita H. Intentional switch between 1.5-mm and 1.25-mm burrs along with switch between rotawire floppy and extra-support for an uncrossable calcified coronary lesion. J Cardiol Cases. 2019;19(6):200–3.CrossRefPubMedPubMedCentral Taniguchi Y, Sakakura K, Mukai Y, Yamamoto K, Momomura SI, Fujita H. Intentional switch between 1.5-mm and 1.25-mm burrs along with switch between rotawire floppy and extra-support for an uncrossable calcified coronary lesion. J Cardiol Cases. 2019;19(6):200–3.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Mizuno Y, Sakakura K, Jinnouchi H, Taniguchi Y, Tsukui T, Yamamoto K, et al. Comparison of the incidence of periprocedural myocardial infarction between percutaneous coronary intervention with versus without rotational atherectomy using propensity score-matching. Sci Rep. 2021;11(1):11140.CrossRefPubMedPubMedCentral Mizuno Y, Sakakura K, Jinnouchi H, Taniguchi Y, Tsukui T, Yamamoto K, et al. Comparison of the incidence of periprocedural myocardial infarction between percutaneous coronary intervention with versus without rotational atherectomy using propensity score-matching. Sci Rep. 2021;11(1):11140.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kübler P, Zimoch W, Kosowski M, Tomasiewicz B, Rakotoarison O, Telichowski A, et al. The use of rotational atherectomy in high-risk patients: results from a high-volume centre. Kardiol Pol. 2018;76(9):1360–8.CrossRefPubMed Kübler P, Zimoch W, Kosowski M, Tomasiewicz B, Rakotoarison O, Telichowski A, et al. The use of rotational atherectomy in high-risk patients: results from a high-volume centre. Kardiol Pol. 2018;76(9):1360–8.CrossRefPubMed
15.
Zurück zum Zitat Sakakura K, Funayama H, Taniguchi Y, Tsurumaki Y, Yamamoto K, Matsumoto M, et al. The incidence of slow flow after rotational atherectomy of calcified coronary arteries: a randomized study of low speed versus high speed. Catheter Cardiovasc Interv. 2017;89(5):832–40.CrossRefPubMed Sakakura K, Funayama H, Taniguchi Y, Tsurumaki Y, Yamamoto K, Matsumoto M, et al. The incidence of slow flow after rotational atherectomy of calcified coronary arteries: a randomized study of low speed versus high speed. Catheter Cardiovasc Interv. 2017;89(5):832–40.CrossRefPubMed
16.
Zurück zum Zitat Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62(17):1563–70.CrossRefPubMedPubMedCentral Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62(17):1563–70.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Yamamoto K, Sakakura K, Taniguchi Y, Tsurumaki Y, Wada H, Momomura SI, et al. Trapping balloon technique for removal of the burr in rotational atherectomy. Int Heart J. 2018;59(2):399–402.CrossRefPubMed Yamamoto K, Sakakura K, Taniguchi Y, Tsurumaki Y, Wada H, Momomura SI, et al. Trapping balloon technique for removal of the burr in rotational atherectomy. Int Heart J. 2018;59(2):399–402.CrossRefPubMed
18.
Zurück zum Zitat Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRefPubMed Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRefPubMed
19.
Zurück zum Zitat Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chuang YC, et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995;91(7):1959–65.CrossRefPubMed Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chuang YC, et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995;91(7):1959–65.CrossRefPubMed
20.
Zurück zum Zitat Thandra A, Pajjuru V, Jhand A, Ponamgi S, Ismayl M, Torres RC, et al. Sex difference in clinical and procedural outcomes in patients undergoing coronary atherectomy: a systematic review and meta-analysis. Coron Artery Dis. 2022;33(8):634–42.CrossRefPubMed Thandra A, Pajjuru V, Jhand A, Ponamgi S, Ismayl M, Torres RC, et al. Sex difference in clinical and procedural outcomes in patients undergoing coronary atherectomy: a systematic review and meta-analysis. Coron Artery Dis. 2022;33(8):634–42.CrossRefPubMed
21.
Zurück zum Zitat Sakakura K, Inohara T, Kohsaka S, Amano T, Uemura S, Ishii H, et al. Incidence and determinants of complications in rotational Atherectomy: insights from the national clinical data (J-PCI Registry). Circ Cardiovasc Interv. 2016;9(11): e004278.CrossRefPubMed Sakakura K, Inohara T, Kohsaka S, Amano T, Uemura S, Ishii H, et al. Incidence and determinants of complications in rotational Atherectomy: insights from the national clinical data (J-PCI Registry). Circ Cardiovasc Interv. 2016;9(11): e004278.CrossRefPubMed
22.
Zurück zum Zitat Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, et al. SGLT-2 Inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497–506.CrossRefPubMed Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, et al. SGLT-2 Inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497–506.CrossRefPubMed
Metadaten
Titel
Halftime rotational atherectomy: a unique concept for diffuse long severely calcified lesions
verfasst von
Kenichi Sakakura
Hiroyuki Jinnouchi
Yousuke Taniguchi
Takunori Tsukui
Yusuke Watanabe
Kei Yamamoto
Masaru Seguchi
Hideo Fujita
Publikationsdatum
10.11.2023
Verlag
Springer Nature Singapore
Erschienen in
Cardiovascular Intervention and Therapeutics / Ausgabe 1/2024
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-023-00968-1

Weitere Artikel der Ausgabe 1/2024

Cardiovascular Intervention and Therapeutics 1/2024 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.